Published on 12/06/2019 10:55:20 AM | Source: Equirus Securities Ltd

Update On Dr Lal PathLabs Ltd By Equirus Securities

Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel 

Download Telegram App before Joining the Channel

Now Get news on WhatsApp. Click Here To Know More

Volumes hit by stretched winter season; growth outlook robust — Upgrade to LONG

Dr. Lal Pathlabs’ (DLPL) 4QFY19 sales at Rs 3.01bn (+13% yoy/+3% qoq) came in 2% below EE amid tepid patient volume growth (12.5%) owing to a stretched winter in the North. However, we expect the company to witness solid volume growth with rising contribution from the ex-Delhi NCR region, along with the Kolkata laboratory ramp-up; that said, realization per patient could be under pressure with increasing share of other regions (outside Delhi NCR), partly offset by the high-margin Swasth franchise. Overall, we expect robust topline/earnings CAGR of 15%/20% over FY19-FY22 with ROE/core ROIC improving to 24%/59% in FY22 from 23%/51% in FY19. Upgrade to LONG (from ADD) with a Sep’20 TP of Rs 1,234 (Mar’20 TP: Rs 1,154 earlier) set by assigning 37x P/E (unchanged).


Stretched winters in 4Q hit patient volumes:

Sales at Rs 3.01bn (+13% yoy/+3% qoq) came in 2% below EE. Volume growth at 12.5% was below our estimates but was partly compensated by better realizations owing to lower promotional testing. Tepid growth in volumes stemmed from a stretched winter in the northern region and a higher 4QFY18 base. EBITDA at Rs 662mn (+3% yoy/+1% qoq) fell 12% short of EE due to lower revenues and higher employee expenses (incl. one-offs of Rs 30mn). PAT grew 17% yoy/3% qoq to Rs 471mn, 6% below EE. Adj. for one-offs related to employee expenses, PAT was broadly in line with EE.


New reference lab progressing well, break even by FY21:

Management stated that the eastern region grew 20% yoy, outpacing company growth of 13.9% in value terms; in volume terms, the region is growing at a robust 25%. This should help the company’s Kolkata lab attain breakeven levels by FY21; also, strong growth indicates DLPL’s improving brand recall and market share in the region.


Swasth (preventive bundled package) gains from a low base:

Swasth contributed 14%/13% to 4Q/FY19 revenues. Higher share of Swasth pushed up overall patient realizations by 2% qoq and also aided per patient tests which rose to 2.38 (from 2.27 earlier). We expect Swasth packages to grow at a higher rate in the coming years on

(a) a low base,

(b) higher incidence of chronic diseases (diabetes, cancer, cardiovascular), and

(c) rising affordability, eventually leading to higher realizations.


Growth blueprint on anvil for southern, western regions:

DLPL intends to follow a cluster approach for western and southern regions with a focus only on Bengaluru and Pune (both contributing Rs 200mn each) and will eye acquisitions to expand the revenue base. Management stated that more than valuations, finding a quality asset is proving to be more difficult for the company.


To Read Complete Report & Disclaimer Click Here


Above views are of the author and not of the website kindly read disclaimer